In the Spotlight August 2004

The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Calculating the amount of drug needed for compounding requires different considerations for respective drug types and forms.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Development of the state-of-the-art facility was made possible by a £2 million (US$2.6 million) round of funding, and a successful inspection by MHRA was completed in March 2025.

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.